Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Industry Insights

Science and business issues impacting the China biotech industry...

2022 China Life Science Deals: Slow Start, Late Recovery; Top 10 Deals Worth $21.5 Billion

Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs

NovoCodex Starts China Trial of anti-CD70 ADC in Solid Tumors

Sirnaomics Reports 100% Complete Response for Lead siRNA Candidate

Sino Biological Partners AI Antibody Development Prediction Platform for CRO

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China